Section Arrow
Quote
KROS.NASDAQ
- Keros Therapeutics
Quotes are at least 15-min delayed:2026/01/10 15:57 EST
Regular Hours
Last
 19.2
+0.62 (+3.34%)
Day High 
19.49 
Prev. Close
18.58 
1-M High
22.2 
Volume 
459.11K 
Bid
18.75
Ask
19.32
Day Low
18.72 
Open
18.87 
1-M Low
17.51 
Market Cap 
566.06M 
Currency 美元 
P/E 12.06 
%Yield -- 
10-SMA 19.5 
20-SMA 20.34 
50-SMA 18.48 
52-W High 22.55 
52-W Low 9.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.56/-5.21
Enterprise Value
582.94M
Balance Sheet
Book Value Per Share
23.09
Cash Flow
Cash Flow Yield
0.12
Income Statement
Total Revenue
3.55M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4944+0.11+28.62%-- 
ASBPAspire Biopharma Holdings Inc.0.104+0.0007+0.68%-- 
RVMDRevolution Medicines118.64+11.25+10.48%-- 
ARDXArdelyx7.74+0.74+10.57%-- 
SLSSELLAS Life Sciences Group3.46-0.4-10.36%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.